Claritas Pharmaceuticals, Inc.
CLAZF · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $2 | $282 | $28 | $5 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $102 | $102 | $108 | $206 |
| Inventory | $16 | $0 | $0 | $763 |
| Other Curr. Assets | $10,913 | $10,763 | $1,047 | $0 |
| Total Curr. Assets | $11,017 | $11,147 | $1,183 | $975 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $1,294 | $1,770 |
| Intangibles | $0 | $0 | $5,627 | $7,694 |
| Long-Term Investments | $7 | $8 | $5 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $6 |
| Total NC Assets | $7 | $8 | $6,926 | $9,470 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $11,024 | $11,155 | $8,109 | $10,445 |
| Liabilities | – | – | – | – |
| Payables | $371 | $417 | $951 | $908 |
| Short-Term Debt | $538 | $542 | $406 | $925 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $961 | $877 | -$951 | $0 |
| Other Curr. Liab. | $6,824 | $6,740 | $5,281 | $5,295 |
| Total Curr. Liab. | $7,733 | $7,699 | $6,638 | $7,128 |
| LT Debt | $10 | $694 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $1,294 | $1,770 |
| Other NC Liab. | $0 | $0 | $1 | $40 |
| Total NC Liab. | $10 | $694 | $1,295 | $1,810 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $7,743 | $8,393 | $7,933 | $8,938 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $62,260 | $62,014 | $57,484 | $0 |
| Retained Earnings | -$59,071 | -$59,252 | -$57,308 | -$55,007 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $92 | $0 | $0 | $56,514 |
| Total Equity | $3,281 | $2,762 | $176 | $1,507 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $11,024 | $11,155 | $8,109 | $10,445 |
| Net Debt | $546 | $954 | $378 | $920 |